Drugs / BB-1701
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04257110 | Jul 2020 → Aug 2024 | carcinoma | Bliss Biopharmaceutical (Hangzhou) Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06188559 | Apr 2024 → Mar 2026 | breast cancer | Eisai Inc. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-05-08 | Eisai Inc. | EISAI ENTERS INTO JOINT DEVELOPMENT AGREEMENT WITH BLISSBIO FOR ANTIBODY DRUG CONJUGATE BB-1701 WITH OPTION RIGHTS FOR STRATEGIC COLLABORATION eisai.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BB-1701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06188559 ↗ |
| Route | Intravenous | “BB-1701 will be administered as an intravenous infusion” NCT04257110 ↗ |